Cross Cancer Institute
Edmonton, Alberta, Canada
55 recruiting
Showing 1–20 of 97 trials
Recruiting
Phase 2Phase 3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled500 locationsNCT05987241
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Genentech, Inc.186 enrolledNCT04910568
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.626 enrolled770 locationsNCT04613596
Recruiting
Phase 3
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
Advanced Head and Neck Cancer
Canadian Cancer Trials Group196 enrolled9 locationsNCT06641791
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled85 locationsNCT06172478
Recruiting
Phase 2
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Cancer
Canadian Cancer Trials Group60 enrolled11 locationsNCT03847649
Recruiting
Phase 2
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Mantle Cell Lymphoma
Canadian Cancer Trials Group40 enrolled3 locationsNCT07341191
Recruiting
Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Endometrial Cancer
Canadian Cancer Trials Group393 enrolled114 locationsNCT05640999
Recruiting
Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials
Cancer
Canadian Cancer Trials Group1,000 enrolled8 locationsNCT07390435
Recruiting
Phase 3
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Multiple Myeloma
Canadian Cancer Trials Group570 enrolled28 locationsNCT06182774
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
CRC (Colorectal Cancer)
Incyte Corporation700 enrolled255 locationsNCT07284849
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Breast CancerLung Cancer
Bristol-Myers Squibb416 enrolled61 locationsNCT06618287
Recruiting
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Pancreatic CancerCancer
British Columbia Cancer Agency190 enrolled4 locationsNCT02869802
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled84 locationsNCT04973605
Recruiting
Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Grade 2 MeningiomaIntracranial Meningioma
NRG Oncology163 enrolled215 locationsNCT03180268
Recruiting
Phase 3
Vorasidenib Maintenance for IDH Mutant Astrocytoma
IDH-mutant Grade 2 or 3 Astrocytoma
European Organisation for Research and Treatment of Cancer - EORTC468 enrolled33 locationsNCT06809322
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled127 locationsNCT05006716
Recruiting
Phase 2
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
Neuroendocrine Tumors
Australasian Gastro-Intestinal Trials Group78 enrolled12 locationsNCT06345079
Recruiting
Phase 3
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Metastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more
National Cancer Institute (NCI)365 enrolled257 locationsNCT06422806
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled352 locationsNCT06065748